Drugs / imilecleucel-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01684761 | Aug 2012 → Oct 2016 | secondary progressive multiple sclerosis | Opexa Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imilecleucel-T | “The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy) is effective in the treatment of secondary progressive multiple...” NCT01684761 ↗ |
| Known as | Tcelna | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01684761 ↗ |
| Modality | Cell therapy | “Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy)” NCT01684761 ↗ |
| Route | Subcutaneous | “two annual courses of 5 subcutaneous doses each year” NCT01684761 ↗ |